secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001628280-24-009807
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics reports Q4 2023 financial results and pipeline updates; soticlestat Phase 3 enrollment complete
--------------------------------------------------------------------------------

- Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet syndromes completed enrollment; Takeda expects topline data by September 2024.
- Cash and marketable securities of $105.8M as of Dec 31, 2023; expected runway into first half of 2026.
- OV888 (GV101) Phase 1 multiple-ascending dose study progressing; no serious adverse events; higher dose cohort added.
- Net loss of $52.3M for full year 2023 compared to $54.2M in 2022; basic net loss per share $0.74.
- Ovid retains 87% interest in soticlestat milestones and royalties; potential payments up to $660M plus low double-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/0001628280-24-009807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/ovid-20240308.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-009807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer